<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486317</url>
  </required_header>
  <id_info>
    <org_study_id>SMC021A2110</org_study_id>
    <nct_id>NCT00486317</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis</brief_title>
  <official_title>SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Bioscience A/S</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to expose patients with OA to calcitonin and to determine plasma
      calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin and 200 IU nasal
      calcitonin. Also the purpose is to assess the effect of different doses of oral calcitonin
      (0.6 mg and 0.8 mg oral) and 200 IU nasal calcitonin compared to placebo on serum CTX-I and
      CTX-II. Finally to assess the tolerance profile of different doses/formulations of oral
      calcitonin compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Urine CTX-I and CTX-II</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum osteocalcin</measure>
  </secondary_outcome>
  <condition>Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral salmon calcitonin, salmon calcitonin nasal spray</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medical history and symptoms of knee osteoarthritis

        Exclusion Criteria:

          -  Any other disease or medication affecting the bone or cartilage.

          -  Any clinical signs or laboratory evidence diseases, which in the Investigator's
             opinion would preclude the participant from adhering to the Protocol or completing the
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>52 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bente J Riis, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Nordic Bioscience A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2007</study_first_posted>
  <last_update_submitted>June 13, 2007</last_update_submitted>
  <last_update_submitted_qc>June 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2007</last_update_posted>
  <keyword>Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

